Giovanni Spagnolli

Giovanni Spagnolli

Company: Sibylla Biotech

Job title: Chief Technology Officer


Panel Discussion: A Critical Review – What Will it Take to Progress Degraders Towards & Through the Clinic? 2:45 pm

Targeted Protein Degradation continues to progress as a therapeutic with huge potential, and 2023 is shaping up to be a landmark year for the degradation community. With the emergence of over 88 newly disclosed TPD drugs in the first half of 2022, over 67 TPD drug updates and critical collaboration, this community continues to advance…Read more

day: Day Two

5:00 Triggering the Degradation of a Target Protein by Interfering with its Folding Pathway 9:45 am

Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT) is a new approach in drug discovery. It is based on the rationale of decreasing the levels of a protein of interest (POI) by interfering with its folding pathway Sibylla Biotech has developed a computational platform that allows the identification of small molecules capable of triggering the…Read more

day: Day 1 Track A afternoon

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.